A new brush sweeps clean†: the case for antiviral treatment of Alzheimer’s disease

Written by Ruth F Itzhaki (Universities of Manchester & Oxford, UK)

Dementia afflicts over 20 million people worldwide, and the numbers affected will rise as more people survive to old age. The emotional costs to the sufferer and the carer are huge, as are the economic costs – estimated worldwide as US $818 billion, and the cost too will increase with increasing longevity. It is imperative, therefore, that effective treatments are found so that the social and economic consequences are reduced. The main cause of dementia is Alzheimer’s disease (AD), accounting for approximately 60% of cases. Aβ and P‐tau are implicated in disease progression but the causes of their formation are...

To view this content, please register now for access

It's completely free